Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
暂无分享,去创建一个
S. Fox | A. Harris | M. Papotti | D. Generali | M. Brizzi | A. Bottini | F. Buffa | L. Dogliotti | A. Berruti | A. Bersiga | S. Bonardi | L. Campo | G. Allevi | M. Milani | S. Aguggini
[1] S. Fox,et al. Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer , 2007, Breast Cancer Research.
[2] Stephen B Fox,et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] S. Fox,et al. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. , 2006, Endocrine-related cancer.
[4] Manuela Milani,et al. Hypoxia-Inducible Factor-1α Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer , 2006, Clinical Cancer Research.
[5] S. Fox,et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Mouret-Reynier,et al. Neoadjuvant endocrine therapy in breast cancer. , 2006, Breast.
[7] H. Stein,et al. Analysis of FOXP3 protein expression in human CD4(+)CD25(+) regulatory T cells at the single-cell level. , 2006, European journal of immunology.
[8] Manuela Milani,et al. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] R. Schiff,et al. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators , 2005, Cancer Chemotherapy and Pharmacology.
[10] I. Hedenfalk,et al. ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERα: a combination therapy potentially targeting hypoxic and dormant tumor cells , 2005, Oncogene.
[11] L. Carey,et al. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. , 2005, Journal of the National Cancer Institute.
[12] M. Dowsett,et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] R. Nicholson,et al. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. , 2005, Endocrine-related cancer.
[14] I. Ellis,et al. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. , 2005, Endocrine-related cancer.
[15] Gauri Sabnis,et al. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. , 2005, Cancer research.
[16] Fiona Powrie,et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single‐cell level , 2005, European journal of immunology.
[17] H. Zou,et al. Regularization and variable selection via the elastic net , 2005 .
[18] S. Verma,et al. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution? , 2005, Cancer treatment reviews.
[19] R. Schiff,et al. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. , 2005, Clinical Cancer Research.
[20] M. Dowsett,et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] R. Fisher,et al. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Manuel Hidalgo,et al. Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity , 2004, Clinical Cancer Research.
[23] A. Harris,et al. Differential Function of the Prolyl Hydroxylases PHD1, PHD2, and PHD3 in the Regulation of Hypoxia-inducible Factor* , 2004, Journal of Biological Chemistry.
[24] L. Murphy,et al. Phospho-Serine-118 Estrogen Receptor-α Expression Is Associated with Better Disease Outcome in Women Treated with Tamoxifen , 2004, Clinical Cancer Research.
[25] S. Ziegler,et al. Cutting Edge: Estrogen Drives Expansion of the CD4+CD25+ Regulatory T Cell Compartment1 , 2004, The Journal of Immunology.
[26] C. Sweep,et al. Vascular endothelial growth factor levels do not predict efficacy of systemic adjuvant treatment as assessed in 1127 breast cancer patients. , 2004, International journal of oncology.
[27] S. Fox,et al. Expression of the Forkhead Transcription Factor FOXP1 Is Associated with Estrogen Receptor α and Improved Survival in Primary Human Breast Carcinomas , 2004, Clinical Cancer Research.
[28] L. Murphy,et al. Phospho-Serine-118 Estrogen Receptor-α Detection in Human Breast Tumors in Vivo , 2004, Clinical Cancer Research.
[29] R. Nicholson,et al. Nonendocrine Pathways and Endocrine Resistance , 2004, Clinical Cancer Research.
[30] L. Murphy,et al. Phospho-serine-118 estrogen receptor-alpha detection in human breast tumors in vivo. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] C. Osborne,et al. Steroid hormone receptors in breast cancer management , 2004, Breast Cancer Research and Treatment.
[32] C. Osborne,et al. Mechanisms of tamoxifen resistance , 2004, Breast Cancer Research and Treatment.
[33] A. Brodie,et al. Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. , 2003, Cancer research.
[34] A. Barqawi,et al. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma , 2003, Cancer.
[35] G. Semenza. Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.
[36] H. Iwata,et al. Clinical significance of the expression of estrogen receptors α and β for endocrine therapy of breast cancer , 2003, Cancer Chemotherapy and Pharmacology.
[37] Mitch Dowsett,et al. Aromatase inhibitors in breast cancer. , 2003, The New England journal of medicine.
[38] M. Dowsett,et al. Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation* , 2003, Journal of Biological Chemistry.
[39] R. Nicholson,et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. , 2003, Endocrinology.
[40] G. Semenzato. TARGETING HIF-1 FOR CANCER THERAPY , 2003 .
[41] H. Iwata,et al. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. , 2003, Cancer chemotherapy and pharmacology.
[42] H. Kurokawa,et al. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[43] D. Coradini,et al. Hypoxia and estrogen receptor profile influence the responsiveness of human breast cancer cells to estradiol and antiestrogens , 2003, Cellular and Molecular Life Sciences CMLS.
[44] M. Dowsett,et al. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation , 2002, The Journal of Steroid Biochemistry and Molecular Biology.
[45] A. Brodie,et al. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[46] H. Nagasawa,et al. Design, synthesis and biological activities of antiangiogenic hypoxic cytotoxin, triazine-N-oxide derivatives. , 2002, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.
[47] Adrian L. Harris,et al. Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.
[48] J. Slingerland,et al. Constitutive MEK/MAPK Activation Leads to p27Kip1Deregulation and Antiestrogen Resistance in Human Breast Cancer Cells* , 2001, The Journal of Biological Chemistry.
[49] M. Ellis,et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[50] J. Kurebayashi,et al. Hypoxia Reduces Hormone Responsiveness of Human Breast Cancer Cells , 2001, Japanese journal of cancer research : Gann.
[51] A. Harris,et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] Simak Ali,et al. Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α , 2001, The Journal of Biological Chemistry.
[53] A. Lenferink,et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. , 2000, Cancer research.
[54] M. Brizzi,et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[55] D. Mottet,et al. ERK activation upon hypoxia: involvement in HIF‐1 activation , 2000, FEBS letters.
[56] J. Pouysségur,et al. p42/p44 Mitogen-activated Protein Kinases Phosphorylate Hypoxia-inducible Factor 1α (HIF-1α) and Enhance the Transcriptional Activity of HIF-1* , 1999, The Journal of Biological Chemistry.
[57] J. Robertson,et al. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. , 1999, Endocrine-related cancer.